Partnership Opportunities

Immunological Disorders

Precision medicine for cell immunotherapies

Technology Overview

Dr. Scott Furlan is using gene-expression profiling, including single-cell analysis, to improve cell-based immunotherapy. He uses high-throughput techniques to generate transcriptional signatures of immune cells including T regulatory cells and chimeric antigen receptor (CAR) T cells to characterize their responses to new microenvironments. He also uses the results to predict pathogenic developments and identify therapeutic targets.

Scott FurlanDr. Scott Furlan

Dr. Furlan’s laboratory has the capability for full analysis, from isolation of single cells and profiling with RNA-seq and other methods, through sophisticated bioinformatic processing of the resulting data. Dr. Furlan is particularly interested in immune cell responses that lead to pathologies such as graft versus host disease. His methods can also be applied to analyzing ex vivo-expanded cells used for adoptive immunotherapy. For example, transcriptome analysis may identify factors associated with poor immunotherapy outcomes such as lack of CAR T cell function or persistence after infusion into patients.

Dr. Furlan is interested in contributing to collaborations that use his expertise in generating cell signatures that reflect the fate of engineered therapeutic cells over time. He has experience working with model organisms including mice and nonhuman primates and translating the results into markers for patient outcomes and targets for new therapies. He also has clinical experience in cancer biology that includes care for bone marrow-transplant patients.

Stage of Development

  • Pre-clinical in vitro
  • Pre-clinical in vivo
  • Pre-clinical ex vivo

Partnering Opportunities

  • Collaborative research opportunity
  • Sponsored research agreement
  • Consultation agreement
  • High-throughput screening
  • Tissue sample access


  1. Cao J, Packer JS, Ramani V, Cusanovich DA, …. Furlan SN, … Shendure J. Comprehensive single-cell transcriptional profiling of a multicellular organism. Science. 2017; 357:661-667.
  2. Furlan SN, Watkins B, Tkachev V, Cooley S, Panoskaltsis-Mortari A, et al. Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and man. Blood. 2016; 128:2568-2579.
  3. Furlan SN, Watkins B, Tkachev V, Flynn R, Cooley S, et al. Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Sci Transl Med. 2015; 7:315ra191.

Learn More

To learn more about partnering with Seattle Children’s Research Institute on this or other projects, please contact:

Dr. Elizabeth Aylward, Director 
Office of Science-Industry Partnerships 
Seattle Children’s Research Institute 
818 Stewart Street, Suite 603
Seattle, WA 98101